Bibliometric analysis of the scientific production as regards statin use for ophthalmological symptoms of myasthenia gravis.
BACKGROUND
The first symptoms of myasthenia gravis (MG) usually involve weakness of the ocular muscles, making it relevant that ophthalmologists have updated information on studies as regards its relationship with the consumption of drugs, such as statins.


METHODS
A bibliometric analysis was performed using the Scopus database and by a search strategy in the selection of documents containing descriptors related to statins in the «Title» («TI») field and the descriptors «ophthalm *', «myast *', «visual *' in other fields of the document (period 1986-2015).


RESULTS
The results showed that, while the number of scientific publications on ocular effects of statins has grown lineally (n=838; y=2.267x-4507.1; r=0.7221; time of duplication: 4.66 years, and rate of annual growth: 50.06%), the specific publications about MG have experienced an exponential growth (n=38; y=2E-262e0.3001x; r=0.3892; time of duplication: 2.95 years, and rate of annual growth: 46.25%) without reaching the saturation postulated in Price theory of the expansion of the scientific literature. The majority of publications relating to MG are reports of cases linked to a worsening of the MG symptoms, and simvastatin and atorvastatin are the agents mentioned in most of the publications.


CONCLUSIONS
These results should enable ophthalmologists to expand their knowledge concerning the evolution of studies on statins and MG, pointing out the relevance of such causal relationships.
Vicerrectorado de Innovación, Universidad Camilo José Cela, Madrid, España. Electronic address: smsalado@ucjc.edu.
S M
SM
Salado-Font
Facultad de Salud, Universidad Camilo José Cela, Madrid, España; Instituto de Investigación, Hospital 12 de Octubre, Madrid, España; Red de Investigación Cooperativa en Salud (RETICS-Red de Trastornos Adictivos), Instituto de Salud Carlos III, Madrid, España.
F
F
López-Muñoz
Centro Óptico Montero, Madrid, España.
F J
FJ
Povedano-Montero
Vicedecanato de Ordenación Académica y Estudiantes, Facultad de Medicina, Universidad de Córdoba, Córdoba, España.
F
F
Labella Quesada
D000069059:Atorvastatin / Q000009:adverse effects; D015706:Bibliometrics; D001763:Blepharoptosis / Q000139:chemically induced / Q000209:etiology*; D015984:Causality; D004172:Diplopia / Q000139:chemically induced / Q000209:etiology*; D004198:Disease Susceptibility; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D009157:Myasthenia Gravis / Q000150:complications*; D009885:Ophthalmology; D019821:Simvastatin / Q000009:adverse effects
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069059:Atorvastatin; D019821:Simvastatin
Bibliometry; Bibliometría; Estatinas; Manifestaciones otftalmológicas; Miatenia gravis; Myasthenia gravis; Ophthalmological manifestations; Statins